Q-omics provides the consensus-scored FUNDC2P4 profile across patient tissues and cancer cell-line models. FUNDC2P4 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, FUNDC2P4 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, FUNDC2P4 RNA expression shows 9,610 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where FUNDC2P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FUNDC2P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FUNDC2P4 survival associations across molecular data types. FUNDC2P4 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FUNDC2P4 RNA expression–survival associations across cancer types. High FUNDC2P4 expression shows unfavorable associations in LIHC and ACC, but favorable associations in SKCM, CESC, BRCA and ESCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for FUNDC2P4 RNA expression.
This table summarizes FUNDC2P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FUNDC2P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FUNDC2P4 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, CHOL, LUAD and THCA. The KIRC box plot shows higher FUNDC2P4 RNA expression in tumor versus normal tissue (log2 FC = +0.130, t-test p < 0.001).
This table shows molecular features associated with FUNDC2P4 in patient tissues and cancer cell lines. In patient samples, FUNDC2P4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
